Certara to Participate in the Stephens Annual Investment Conference
RADNOR, Pa. — October 28, 2024 -- Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraOctober 28, 2024
Certara Appoints John Reynders as New Independent Board Member
RADNOR, PA., October 16, 2024 — Certara, Inc. (Nasdaq: CERT), a global leader in model-informed…
CertaraOctober 16, 2024
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024
Radnor, Pa. — October 9th, 2024-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed…
CertaraOctober 9, 2024
Certara Completes Acquisition of Chemaxon
The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty…
CertaraOctober 2, 2024
Certara’s Simcyp Consortium Celebrates 25th Anniversary
The pre-competitive scientific research consortium of top pharmaceutical companies remains a critical force in advancing…
CertaraSeptember 24, 2024
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to…
CertaraSeptember 18, 2024
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa. — August 21, 2024 -- Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraAugust 21, 2024
Certara Launches Phoenix™ Version 8.5 Drug Development Software
RADNOR, PA – August 15, 2024 - Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraAugust 15, 2024
Certara Reports Second Quarter 2024 Financial Results
Reiterates Full Year 2024 Financial Guidance RADNOR, PA — August 6, 2024-- Certara, Inc. (Nasdaq: CERT),…
CertaraAugust 6, 2024
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
Combined organization brings broader predictive capabilities to drug discovery at scale Reiterates full year 2024…
CertaraJuly 9, 2024
